text
"['\nX. 대주주 등과의 거래내용\n(1) 당분기 및 전분기 중 회사와 매출 등 거래 또는 채권, 채무 잔액이 있는 특수관계자 현황은 다음과 같습니다.\n관 계\n회 \xa0 \xa0 사 \xa0 \xa0 명\n종속기업\n㈜유한화학, ㈜유한메디카, ㈜와이즈메디(구, ㈜엠지), ㈜유한건강생활, 애드파마㈜,YUHAN UZBEKISTAN, Yuhan ANZ Pty Ltd, 암호명케이문화산업전문(유), YUHAN USACORPORATION, ㈜에이투젠, 퍼멘텍㈜\n관계기업 및 공동기업\n유한킴벌리㈜, ㈜유칼릭스, ㈜유한크로락스, ㈜한국얀센, ㈜코스온, ㈜이뮨온시아, ㈜씨.앤.씨, ㈜워랜텍, ㈜지아이이노베이션, ㈜휴이노, ㈜메디오젠, 에스비바이오팜㈜, 메디라마㈜, ㈜제이인츠바이오,㈜테라베스트, ㈜온코마스터, ㈜에이프릴바이오, ㈜프로젠, 메리츠-수성 글로벌바이오 제1호\n기타특수관계자\n㈜리드팜, 류신(칭다오)건강(유), (재)유한재단\n(2) 당분기 및 전분기 중 특수관계자와의 거래 내역은 다음과 같습니다.\n- 당분기\n\xa0(단위:천원)\n특수관계자의 명칭\n제상품매출\n임대, 용역수익\n기타(잡이익 등)\n배당금수익\n매입 등\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n종속기업 :\n\xa0㈜유한화학\xa0\n1,800\n7,200\n-\n-\n-\n-\n-\n-\n38,779,749\n144,462,878\n\xa0㈜유한메디카\n-\n218\n6,900\n132,454\n-\n-\n-\n-\n-\n-\n\xa0㈜와이즈메디(구, ㈜엠지)\n-\n-\n8,970\n26,910\n-\n-\n-\n-\n5,519,532\n14,899,127\n\xa0㈜유한건강생활\n-\n-\n184,683\n606,100\n3,106\n3,106\n-\n-\n1,637,395\n5,856,371\n\xa0애드파마㈜\n-\n-\n273,423\n276,543\n-\n-\n-\n-\n5,009,912\n8,460,969\n\xa0㈜에이투젠\n-\n-\n-\n-\n-\n-\n-\n-\n1,961,456\n2,757,186\n소 계\n1,800\n7,418\n473,976\n1,042,007\n3,106\n3,106\n-\n-\n52,908,044\n176,436,531\n관계기업 및 공동기업 :\n\xa0유한킴벌리㈜\n-\n-\n-\n-\n-\n-\n-\n20,700,000\n-\n-\n\xa0㈜유한크로락스\n-\n2,755\n381,346\n1,154,231\n2,050,644\n4,049,955\n-\n1,868,300\n24,900,178\n60,954,475\n\xa0㈜한국얀센\n-\n-\n-\n62,442\n-\n-\n-\n5,529,000\n10,280,385\n31,293,186\n\xa0㈜유칼릭스\n-\n-\n-\n-\n-\n-\n-\n40,800\n21,662\n64,825\n\xa0㈜이뮨온시아\n-\n-\n936\n2,808\n-\n-\n-\n-\n-\n-\n\xa0㈜씨.앤.씨\n-\n-\n-\n-\n-\n-\n-\n-\n1,083,521\n4,549,692\n\xa0㈜워랜텍\n-\n3,680\n-\n-\n-\n-\n-\n-\n92,619\n2,053,321\n\xa0㈜지아이이노베이션\n-\n-\n-\n-\n464,500\n4,098,000\n-\n-\n-\n-\n\xa0㈜휴이노\n-\n-\n-\n-\n-\n-\n-\n-\n(1,724,565)\n(1,737,315)\n\xa0㈜메디오젠\n-\n-\n-\n-\n-\n-\n-\n11,728\n523,006\n1,555,564\n\xa0에스비바이오팜㈜\n-\n-\n76,800\n230,400\n-\n1,300\n-\n-\n870,351\n2,232,173\n\xa0메디라마㈜\n-\n-\n21,987\n66,161\n-\n-\n-\n-\n-\n20,000\n\xa0파라투스에스피사모투자(합)(*)\n-\n-\n-\n-\n-\n-\n-\n6,631,427\n-\n30,029,960\n소 계\n-\n6,435\n481,069\n1,516,042\n2,515,144\n8,149,255\n-\n34,781,255\n36,047,157\n131,015,881\n기타특수관계자 :\n\xa0㈜리드팜\n1,058,081\n2,236,138\n-\n-\n-\n-\n-\n-\n785\n1,777\n\xa0류신(칭다오)건강(유)\n-\n-\n-\n-\n-\n-\n-\n-\n10\n121\n\xa0(재)유한재단\n-\n-\n4,706\n12,834\n-\n-\n-\n-\n-\n-\n소 계\n1,058,081\n2,236,138\n4,706\n12,834\n-\n-\n-\n-\n795\n1,898\n합 계\n1,059,881\n2,249,991\n959,751\n2,570,883\n2,518,250\n8,152,361\n-\n34,781,255\n88,955,996\n307,454,310\n(*) 관계기업에 제외되기 전까지의 거래내역입니다.\n- 전분기\n\xa0(단위:천원)\n특수관계자의 명칭\n제상품매출\n임대, 용역수익\n기타(잡이익 등)\n배당금수익\n매입 등\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n종속기업 :\n\xa0㈜유한화학\xa0\n-\n3,600\n-\n-\n-\n-\n-\n-\n29,757,127\n122,884,015\n\xa0㈜유한메디카\n-\n159\n6,900\n20,700\n-\n-\n-\n-\n760,597\n760,597\n\xa0㈜와이즈메디(구, ㈜엠지)\n-\n-\n8,970\n26,910\n-\n-\n-\n-\n4,533,440\n11,834,208\n\xa0㈜유한건강생활\n28,187\n28,187\n199,900\n672,607\n-\n30,000\n-\n-\n2,810,564\n11,742,554\n\xa0애드파마㈜\n-\n-\n1,560\n4,680\n-\n-\n-\n-\n2,480,800\n9,787,118\n소 계\n28,187\n31,946\n217,330\n724,897\n-\n30,000\n-\n-\n40,342,528\n157,008,492\n관계기업 및 공동기업 :\n\xa0유한킴벌리㈜\n-\n-\n-\n-\n-\n-\n-\n97,800,000\n54,000\n255,213\n\xa0㈜유한크로락스\n-\n1,657\n401,241\n1,120,955\n-\n-\n-\n2,198,000\n20,322,840\n56,106,325\n\xa0㈜한국얀센\n-\n-\n78,574\n385,718\n-\n-\n-\n5,536,450\n9,680,102\n29,473,588\xa0\n\xa0㈜유칼릭스\n-\n-\n-\n-\n-\n-\n-\n40,800\n18,156\n53,921\n\xa0㈜엔솔바이오사이언스\n-\n-\n-\n-\n-\n-\n-\n-\n587,010\n587,010\n\xa0㈜이뮨온시아\n-\n-\n936\n22,808\n-\n1,200\n-\n-\n-\n-\n\xa0㈜씨.앤.씨\xa0\n-\n-\n-\n-\n-\n-\n-\n-\n1,918,088\n5,522,661\n\xa0㈜워랜텍\n-\n-\n-\n-\n-\n-\n-\n-\n2,095,592\n5,823,954\n\xa0㈜지아이이노베이션\n-\n-\n-\n-\n-\n-\n-\n-\n3,500,000\n3,500,000\n\xa0㈜휴이노\n-\n-\n-\n-\n-\n-\n-\n-\n975,000\n1,241,150\n\xa0㈜메디오젠\n-\n-\n-\n-\n-\n-\n-\n234,570\n185,900\n2,836,131\n\xa0㈜에이프릴바이오\n-\n-\n-\n-\n-\n-\n-\n-\n200,000\n200,000\n\xa0에스비바이오팜㈜\n-\n-\n-\n-\n-\n-\n-\n-\n(3,518,591)\n(238,004)\n\xa0메디라마㈜\n-\n-\n21,987\n51,303\n-\n-\n-\n-\n60,000\n120,000\n\xa0㈜온코마스터\n-\n-\n1\n1\n-\n-\n-\n-\n-\n-\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0소 계\n-\n1,657\n502,739\n1,580,785\n-\n1,200\n-\n105,809,820\n36,078,097\n105,481,949\n기타특수관계자 :\n\xa0㈜리드팜\n676,283\n2,077,825\n-\n-\n-\n-\n-\n-\n995\n2,918\n\xa0류신(칭다오)건강(유)\n-\n-\n-\n-\n-\n-\n-\n-\n245\n1,872\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0소 계\n676,283\n2,077,825\n-\n-\n-\n-\n-\n-\n1,240\n4,790\n합 계\xa0\n704,470\n2,111,428\n720,069\n2,305,682\n-\n31,200\n-\n105,809,820\n76,421,865\n262,495,231\n(3) 당분기말과 전기말 현재 특수관계자와의 채권ㆍ채무는 다음과 같습니다.\n\xa0(단위:천원)\n회사명\n매출채권\n매입채무\n미수금 등 기타자산\n예수보증금\n당분기말\n전기말\n당분기말\n전기말\n당분기말\n전기말\n당분기말\n전기말\n종속기업 :\n\xa0㈜유한화학\xa0\n-\n-\n17,870,658\n3,464,967\n-\n2,818,802\n-\n-\n\xa0㈜유한메디카\n-\n-\n-\n-\n-\n-\n400,000\n400,000\n\xa0㈜와이즈메디(구, ㈜엠지)\n-\n-\n3,521,429\n3,287,805\n1,700,000\n1,700,000\n520,000\n520,000\n\xa0㈜유한건강생활\n94,660\n159,241\n712,079\n1,618,656\n-\n-\n796,800\n796,800\n\xa0YUHAN UZBEKISTAN\n767,751\n723,506\n-\n-\n-\n-\n-\n-\n\xa0애드파마㈜\n-\n-\n-\n1,422,792\n2,709,703\n918,593\n-\n-\n\xa0㈜에이투젠\n-\n-\n1,718,468\n-\n-\n-\n-\n-\n소 계\n862,411\n882,747\n23,822,634\n9,794,220\n4,409,703\n5,437,395\n1,716,800\n1,716,800\n관계기업 및 공동기업 :\n\xa0㈜유한크로락스\n419,480\n270,334\n27,390,195\n10,773,728\n2,255,708\n-\n-\n-\n\xa0㈜한국얀센\n-\n-\n7,260,643\n6,802,130\n-\n-\n-\n-\n\xa0㈜유칼릭스\n-\n-\n3,758\n6,953\n-\n-\n-\n-\n\xa0㈜코스온\n-\n-\n-\n-\n2,000,000\n-\n-\n-\n\xa0㈜이뮨온시아\n-\n343\n-\n-\n-\n-\n-\n\xa0㈜씨.앤.씨\n-\n-\n765,121\n1,010,944\n-\n-\n-\n-\n\xa0㈜워랜텍\n-\n-\n45,289\n1,350,063\n-\n-\n-\n-\n\xa0㈜지아이이노베이션\n-\n-\n-\n-\n-\n-\n-\n-\n\xa0㈜휴이노\n-\n-\n-\n-\n1,885,197\n-\n-\n-\n\xa0㈜메디오젠\n-\n-\n543,149\n72,173\n-\n-\n-\n-\n\xa0에스비바이오팜㈜\n28,160\n-\n937,842\n546,000\n8,667,813\n4,356,179\n250,000\n-\n\xa0메디라마㈜\n8,062\n-\n-\n-\n-\n-\n42,000\n42,000\n소 계\n455,702\n270,677\n36,945,997\n20,561,991\n14,808,718\n4,356,179\n292,000\n42,000\n기타특수관계자 :\n\xa0㈜리드팜\n1,053,196\n416,937\n-\n1,485\n-\n-\n-\n-\n\xa0(재)유한재단\n-\n-\n-\n-\n-\n-\n248,000\n248,000\n소 계\n1,053,196\n416,937\n-\n1,485\n-\n-\n248,000\n248,000\n합 계\n2,371,309\n1,570,361\n60,768,631\n30,357,696\n19,218,421\n9,793,574\n2,256,800\n2,006,800\n(4) 당분기 및 전분기 중 특수관계자와의 자금거래 내역은 다음과 같습니다.\n(단위: 천원)\n특수관계 구분\n회사명\n당분기\n전분기\n대여\n출자\n출자\n종속기업\n㈜유한화학\xa0\n-\n-\n30,000,000\nYUHAN UZBEKISTAN\n-\n-\n30,502\n㈜와이즈메디(구, ㈜엠지)\n-\n-\n907,200\n㈜유한건강생활\n-\n-\n6,900,608\nYUHAN USA CORPORATION\n-\n-\n7,713,600\n애드파마㈜\n-\n-\n7,000,000\n암호명케이문화산업전문(유)\n-\n-\n2,400,000\nYuhan ANZ Pty Ltd\n-\n302,671\n-\n㈜에이투젠\n-\n7,000,069\n10,532,691\n퍼멘텍㈜\n-\n5,747,000\n-\n관계기업 및 공동기업\n㈜코스온\n2,000,000\n-\n-\n㈜테라베스트\n-\n-\n2,999,984\n에스비바이오팜㈜\n93,000\n-\n-\n㈜제이인츠바이오\n1,999,996\n1,999,997\n㈜온코마스터\n-\n-\n1,999,850\n메디라마㈜\n-\n1,499,971\n1,499,971\n메리츠-수성 글로벌바이오 제1호\n-\n2,000,000\n-\n㈜프로젠\n-\n29,998,329\n-\n(5) 당분기말 현재 회사가 특수관계자에게 제공한 지급보증 및 담보 내역은 다음과 같습니다.\n(단위: 천원)\n특수관계자의 명칭\n보증 등의 내용\n금융기관\n보증 금액\n종속기업 :\n㈜유한건강생활\n일반대출\n신한은행\n3,600,000\n애드파마㈜\n운전자금대출\n하나은행\n6,000,000\n합 \xa0계\n9,600,000\n(6) 회사는 등기이사 및 회사 기업활동의 계획, 운영 및 통제에 대한 중요한 권한과 책임을 가진 등기 임원을 주요 경영진으로 판단하고 있으며, 당분기 및 전분기 중 주요 경영진에 대한 보상금액은 다음과 같습니다.\n(단위:천원)\n구 \xa0분\n당분기\n전분기\n3개월\n누적\n3개월\n누적\n단기종업원급여\n639,478\n1,758,281\n707,730\n1,847,227\n퇴직급여\n72,558\n217,675\n95,798\n287,393\n합 계\n712,036\n1,975,956\n803,528\n2,134,620\n']"
